1.The determination and significance of VEGF in the serum of hemangioma patients.
Qionghua HU ; Xiaoxi LIN ; Qingxin SHANG ; Jiasheng DONG ; Zuoliang QI ; Wei WANG
Chinese Journal of Plastic Surgery 2002;18(2):98-100
OBJECTIVELooking for an objective biomedical index to distinguish types and phases of hemangioma in order to provide an objective basis for selecting clinical treatment to hemangioma.
METHODSELISA (enzyme-linked immunosorbent assay) was used to determine serum VEGF concentration of 15 patients with proliferative hemangioma, 6 with involuted hemangioma, 6 with vascular malformation and 8 infants of the control group.
RESULTSThe serum VEGF concentrations of 15 proliferative hemangioma patients were significantly higher than those of involuted hemangioma patients, vascular malformation patients and control group infants. The serum VEGF concentrations of involuted hemangioma patients were a little bit higher than those of vascular malformation patients and control group infants, but without statistic significance.
CONCLUSIONSELISA could easily and accurately determine the serum VEGF concentration of different types and different phases of hemangioma. The determination of serum VEGF concentration could provide guidance for selecting a protocol of systemic corticosteroid treatment for proliferative hemangioma. Combined with gene expression and distribution of VEGF and its receptors and some other cytokines, the determination of serum VEGF concentration could help elucidate the mechanism of proliferative hemangioma.
Endothelial Growth Factors ; blood ; Enzyme-Linked Immunosorbent Assay ; Hemangioma ; blood ; Humans ; Infant ; Lymphokines ; blood ; Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factors
2.Value of VEGF-C, VEGF-D and VEGFR-3 levels combined with serum TSH in diagnosis of papillary thyroid carcinoma.
Jing HUANG ; Yanping LI ; Gang XUE ; Wenjing ZHANG ; Shaoying LI ; Jing ZHANG ; Jingfang WU
Journal of Southern Medical University 2014;34(12):1814-1821
OBJECTIVETo investigate serum vascular endothelial growth factor-C (VEGF-C), VEGF-D and VEGFR-3 levels in patients with papillary thyroid carcinoma (PTC) and analyze their relation with the clinicopathological and thyroid function of the patients.
METHODSSerum samples and the data of thyroid function were collected from 55 patients with PTC and 24 with benign thyroid tumor (BT). ELISA was used to detect VEGF-C/D and VEGFR-3 concentration in the serum samples and their relation with the thyroid function was analyzed.
RESULTSThe VEGF-C and VEGFR-3 levels were significantly higher in PTC group than in BT group (P<0.05), but VEGF-D level was comparable between them (P>0.05). In PTC patients, the elevation of serum VEGF-C and VEGFR-3 levels was associated with an advanced clinical stage (III-IV), elevated thyroid-stimulating hormone (TSH) level, an age over 45 years, and a tumor diameter exceeding 2 cm (P<0.05 or P<0.01). Patients with lymph node metastasis had significantly higher VEGF-C level but lower VEGF-3 level than those without metastasis regardless of gender. Serum VEGF-D level was higher in PTC patients with lymph node metastasis (P<0.05) and elevated TSH level (P<0.01) without association with the clinical stage, tumor diameter, age, or gender. The area under ROC curve (AUC) of serum VEGF-C, VEGFR-3 and TSH was 0.803, 0.734 and 0.707 respectively (P<0.01), and that of VEGF-D was 0.556 (P>0.05); when combined, serum VEGF-C, VEGFR-3 and TSH showed an AUC of 0.862 (P<0.01).
CONCLUSIONDetecting serum VEGF-C and VEGFR-3 levels combined with TSH may enhance the early diagnosis rate of papillary thyroid carcinoma.
Carcinoma ; blood ; diagnosis ; Carcinoma, Papillary ; Early Detection of Cancer ; Enzyme-Linked Immunosorbent Assay ; Humans ; Lymphatic Metastasis ; Thyroid Neoplasms ; blood ; diagnosis ; Thyrotropin ; blood ; Vascular Endothelial Growth Factor C ; blood ; Vascular Endothelial Growth Factor D ; blood ; Vascular Endothelial Growth Factor Receptor-3 ; blood
3.Expression of Vascular Endothelial Growth Factor in Hepatocellular Carcinomas.
Seong Woo HONG ; Hee Jung WANG ; Yun Mi JIN ; Wook Hwan KIM ; Eu Young SO ; Myung Wook KIM
Journal of the Korean Surgical Society 1999;57(1):81-85
BACKGROUND: A tumor must continuously stimulate the growth of new capillary blood vessels for the tumor itself to grow and metastasize. Vascular endothelial growth factor (VEGF) promotes vascular permeability and endothelial cell growth. A hepatocellular carcinoma (HCC) is a typical hypervascular tumor. METHODS: We evaluated the expression of VEGF in 36 cases of HCC by using immunohistochemical staining in order to define its prognostic value. RESULTS: The expression rate of VEGF was 44.4% (16/36) in tumor cells and 0% (0/36) in non- tumorous liver parenchyme. VEGF expression did not correlate with any clinicopathological characteristics. And patients with expression of VEGF in tumor cells had no survival difference in comparison to those without VEGF expression. CONCLUSIONS: These results suggest that the expression of VEGF in HCC cells by itself may not be a significant factor in the prognosis of HCC.
Blood Vessels
;
Capillaries
;
Capillary Permeability
;
Carcinoma, Hepatocellular*
;
Endothelial Cells
;
Humans
;
Liver
;
Prognosis
;
Vascular Endothelial Growth Factor A*
4.Expression of vascular endothelial growth factor (VEGF) and VEGF-C in serum and tissue of Wilms tumor.
Lei WANG ; Da ZHANG ; Xin-Rang CHEN ; Yu-Xia FAN ; Jia-Xiang WANG
Chinese Medical Journal 2011;124(22):3716-3720
BACKGROUNDAngiogenesis and lymphogenesis which were promoted by vascular endothelial growth factor (VEGF) and VEGF-C are important in the growth and metastasis of solid tumors. The high level of VEGF and VEGF-C were distributed in numerous types of cancers, but their distribution and expression in Wilms tumor, the most common pediatric tumor of the kidney, was unclear.
METHODSTo learn about the distribution, mass spectroscopy and immunohistochemistry were used to measure the level of VEGF and VEGF-C in serum and tissue of Wilms tumor.
RESULTSThe expression level of VEGF in serum of Wilms tumor was the same as in pre-surgery and control, so it was the same case of VEGF-C. Both of these factors were chiefly located in Wilms tumor tissue, but not in borderline and normal. In addition, the higher clinical staging and histopathologic grading were important elements in high expression of VEGF and VEGF-C. Gender, age and the size of tumor have not certainly been implicated in expression level of VEGF and VEGF-C.
CONCLUSIONSThe lymph node metastasis and growth of tumors resulted from angiogenesis and lymphogenesis which were promoted by VEGF and VEGF-C in Wilms tumor. The autocrine and paracrine process of VEGF and VEGF-C were the principal contributor to specific tissues of Wilms tumor but not to the entire body.
Adolescent ; Child ; Child, Preschool ; Female ; Humans ; Immunohistochemistry ; Infant ; Male ; Mass Spectrometry ; Vascular Endothelial Growth Factor A ; blood ; metabolism ; Vascular Endothelial Growth Factor C ; blood ; metabolism ; Wilms Tumor ; blood ; metabolism
5.The Levels of Circulating Vascular Endothelial Growth Factor and Soluble Flt-1 in Pregnancies Complicated by Preeclampsia.
Eun Sung LEE ; Min Jeong OH ; Jae Won JUNG ; Ji Eun LIM ; Hyun Joo SEOL ; Kyung Ju LEE ; Hai Joong KIM
Journal of Korean Medical Science 2007;22(1):94-98
To evaluate the role of vascular endothelial growth factor (VEGF) in the pathogenesis of preeclampsia, we measured total VEGF, free VEGF and soluble Flt-1 (sFlt-1) concentrations and determined their relationships. Maternal serum samples were collected from 20 patients with preeclampsia and 20 normotensive women with uncomplicated pregnancies matched with the patients with preeclampsia for gestational age and parity. The serum concentrations of total VEGF (2.39+/-0.75 vs. 0.28+/-0.14) and sFlt-1 (934.5+/-235.5 vs. 298.0+/-161.2) were significantly increased in the patients with preeclampsia compared to the women with uncomplicated pregnancies. However the serum concentration of free VEGF (21.5+/-6.3 vs. 134.0+/-16.3) was lower in patients with preeclampsia. There was a positive correlation between the serum concentrations of total VEGF and sFlt-1 with systolic and diastolic blood pressure, respectively. There was a negative correlation between the serum concentration of free VEGF and systolic and diastolic blood pressure. There was a strong negative correlation between free VEGF and sFlt-1 concentrations. In conclusion, we found VEGF and sFlt-1 were related to the pathogenesis of preeclampsia. Although reduced concentrations of free VEGF might interfere with endothelial cell function and survival, further studies are required to clarify its specific role in the pathogenesis of preeclampsia.
Vascular Endothelial Growth Factor Receptor-1/*blood
;
Vascular Endothelial Growth Factor A/*blood/physiology
;
Pregnancy
;
Pre-Eclampsia/*blood/etiology
;
Humans
;
Female
;
Adult
6.Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis.
Sang Hun LEE ; Dongjun JEONG ; Yong Seok HAN ; Moo Jun BAEK
Annals of Surgical Treatment and Research 2015;89(1):1-8
The shaping of new blood vessels is a significant event in cancer growth and metastasis. Therefore, the molecular system of cancer angiogenesis has garnered considerable interest in cancer research. The vascular endothelial growth factor (VEGF) and VEGF receptor pathway are recognized as the key regulators of the angiogenic process. Activation of the VEGF/VEGF-receptor pathway initiates signaling cascades that promote endothelial cell growth, migration, and differentiation. Recently, VEGF was shown to play a role in the recruitment of bone marrow-derived endothelial progenitor cells to neovascularization sites. The role of VEGF in promoting tumor angiogenesis and the occurrence of human cancers has led to the rational design and development of agents that selectively target this pathway. Moreover, these anti-VEGF/VEGF receptor agents show therapeutic potential by inhibition of angiogenesis and tumor growth in preclinical models. In this review, we summarize the role of the VEGF pathway during tumor angiogenesis.
Angiogenesis Inhibitors
;
Blood Vessels
;
Cell Hypoxia
;
Endothelial Cells
;
Humans
;
Neoplasm Metastasis
;
Receptors, Vascular Endothelial Growth Factor
;
Stem Cells
;
Tumor Microenvironment
;
Vascular Endothelial Growth Factor A*
7.Platelets Induce Proliferation of Human Umbilical Vein Endothelial Cells via CD154-CD40 Pathway Independently of VEGF.
Whajung CHO ; Eun Mi KO ; In Su CHEON ; Doo Il JEOUNG ; Young Myeong KIM ; Jongseon CHOE
Immune Network 2008;8(3):75-81
BACKGROUND: Platelets take part in repairing the lesions of endothelial damage. To understand the molecular mechanism of this process, we tested the hypothesis that CD154 expressed on activated platelets stimulates proliferation of human endothelial cells. METHODS: The expression levels of CD154 and CD40 on platelets and endothelial cells, respectively, were measured by flow cytometry and confocal microscopy. Function-blocking monoclonal antibody against CD154 was developed after immunization with CD154- transfected L cells. RESULTS: An anti-CD40 agonist antibody and soluble CD154 both induced significant proliferation of endothelial cells. In addition, a function-blocking anti-CD154 antibody inhibited the platelet-induced proliferation of endothelial cells, indicating that the CD154-CD40 pathway is involved in these cellular interactions. An anti-VEGF antibody failed to inhibit the proliferation. This, in addition to the fact that very small amounts of VEGF are released from platelets or endothelial cells, suggests that VEGF does not play an important role in the platelet-stimulated proliferation of endothelial cells. CONCLUSION: Our results indicate that platelets induce proliferation of endothelial cells by CD154-CD40 interactions independently of VEGF.
Blood Platelets
;
Endothelial Cells
;
Flow Cytometry
;
Human Umbilical Vein Endothelial Cells
;
Humans
;
Immunization
;
Microscopy, Confocal
;
Vascular Endothelial Growth Factor A
8.Changes of serum angiogenesis in patients with chronic mountain sickness.
Jin-Hua YAN ; Zhan-Quan LI ; Lin-Hua JI ; Ke-Xia CHAI ; Ri-Li GE
Chinese Journal of Applied Physiology 2009;25(4):457-460
AIMThe clinical manifestation of chronic mountain sickness (CMS) is polycythemia, pulmonary hypertension and mionectic blood. However, the pathogenesis of it is not identified now. So it is necessary to investigate the effects of the angiogenic growth factors on the pathophysiologic development of CMS.
METHODSThe serum levels of basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) in 13 healthy Tibetan natives (Native), 17 healthy people in Xining (control group) and 35 CMS patients were determined by quantitative sandwich enzyme immunoassay. Meanwhile, the levels of Hb, Hct and SaO2 were determined.
RESULTSThe serum levels of bFGF (107.26 +/- 7.86) ng/L, PDGF (630.18 +/- 9.89) ng/L and VEGF (543.74 +/- 6.76) ng/L in CMS were significantly higher than those in Natives (37.01 +/- 9.16; 292.16 +/- 6.88; 125.51 +/- 7.26) ng/L, and in control group (40.58 +/- 5.34; 287.68 +/- 8.33; 76.26 +/- 4.60) ng/L, respectively (P < 0.01). There was no difference between the natives and the control group in bFGF and PDGF (P > 0.05), while there was predominant difference between the Natives and the control group in VEGF (P < 0.01). There was a predominant positive correlation between the serum levels of bFGF, PDGF or VEGF and hemoglobin concentrations in CMS respectively (P < 0.01). And there were positive relations between angiogenic growth factors each other.
CONCLUSIONThe serum levels of bFGF, PDGF and VEGF in patients with CMS significantly increase, these angiogenic growth factors may play important role on the pathophysiologic development of CMS; the VEGF level likely contributes to the adaptation to plateau hypoxia in healthy Tibetan natives; the elevated bFGF, PDGF and VEGF levels are likely associated with excessive erythropoiesis in CMS.
Adult ; Altitude Sickness ; blood ; Case-Control Studies ; Chronic Disease ; Fibroblast Growth Factor 2 ; blood ; Humans ; Male ; Middle Aged ; Platelet-Derived Growth Factor ; metabolism ; Vascular Endothelial Growth Factor A ; blood
9.Cord Blood Soluble fms-Like Tyrosine Kinase 1 and Placental Growth Factor in Preterm Infants with Maternal Preeclampsia.
Jiyoung KIM ; Sujin CHO ; Young Ju KIM ; Hye Sook PARK ; Eun Hee HA ; Eun Ae PARK
The Ewha Medical Journal 2013;36(2):118-125
OBJECTIVES: The purpose of this study was to investigate the relationship of cord blood levels of soluble fms-like tyrosine kinase 1 (sFlt-1), placental growth factor (PlGF), and vascular endothelial growth factor (VEGF) in preterm infants with maternal preeclampsia. METHODS: Thirty six preterm infants born at Ewha Womans University Mokdong Hospital from January 2006 to August 2006 were studied after prior parental consent at mid-pregnancy. sFlt-1, PlGF, and VEGF levels in the cord blood of preterm neonate, with or without maternal preeclampsia, were measured using enzyme-linked immunosorbent assay. RESULTS: There was no difference in sFlt-1 between infants with and without maternal preeclampsia. Infants with maternal preeclampsia had significantly lower PlGF levels (P=0.035) and higher sFlt-1/PlGF ratio (P=0.080) with borderline significance. Cord blood VEGF levels were not related to maternal preeclampsia. Infants with maternal preeclampsia had lower birth weight (P=0.030), lower neonatal platelet count without statistical significance (P=0.064) and more likely to be small for gestational age (P=0.057). Neonatal platelet count was significantly correlated with cord blood PlGF levels (r=0.674, P=0.032). CONCLUSION: Increased sFlt-1/PlGF ratio and decreased PlGF may not only be related to the pathophysiology of maternal preeclampsia but also affect the neonatal platelet count and birth weight.
Birth Weight
;
Female
;
Fetal Blood*
;
Humans
;
Infant
;
Infant, Newborn
;
Infant, Premature*
;
Parental Consent
;
Platelet Count
;
Pre-Eclampsia*
;
Vascular Endothelial Growth Factor A
;
Vascular Endothelial Growth Factor Receptor-1*
10.Nuclear medical molecular imaging of tumor angiogenesis: current status and future prospects.
Xu-dong HU ; Li-gang XING ; Jin-ming YU
Chinese Medical Journal 2013;126(14):2741-2746
OBJECTIVETo review the current status and progress on nuclear medical molecular imaging of angiogenesis.
DATA SOURCESA literature search was performed in Medline and PubMed published in English up to May 31, 2012. The search terms were molecular imaging, nuclear medicine and angiogenesis.
STUDY SELECTIONArticles studying molecular imaging of angiogenesis using radionuclide were selected and reviewed.
RESULTSMolecular imaging has been used for studying angiogenesis by targeting integrin αVβ3, VEGF/VEGFR, and matrix metalloproteinases (MMPs) with radionuclide-labeled tracers. The technology has been shown to be able to assess the angiogenesis status and/or predict the efficacy of anti-angiogenic therapy. Future directions of the research on the molecular imaging of angiogenesis include development of new tracers with better tumor targeting efficacy, desirable pharmacokinetics, and easy translation to clinical applications.
CONCLUSIONAdvances in molecular imaging of angiogenesis using radioculcide will make the technology a valuable tool for personalized anti-angiogenesis treatment.
Humans ; Integrins ; analysis ; Matrix Metalloproteinases ; analysis ; Neoplasms ; blood supply ; Neovascularization, Pathologic ; diagnosis ; Receptors, Vascular Endothelial Growth Factor ; analysis ; Vascular Endothelial Growth Factor A ; analysis